Download App

Log in to access Online Inquiry
Company Overview More
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead’s antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
CEO: Jabbour J.D., Jerome D.
Market: AMEX
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

MTNB Matinas BioPharma
0.709+0.044+6.60%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Assets
Current assets
Cash, cash equivalents and short term investments
-27.69% 43.87M -15.44% 49.62M -15.44% 49.62M -14.24% 53.83M
-Cash and cash equivalents
-17.34% 19.33M 69.15% 21.03M 69.15% 21.03M 253.45% 24.92M
-Short-term investments
-34.18% 24.54M -38.17% 28.59M -38.17% 28.59M -48.12% 28.91M
Prepaid assets
-48.61% 1.2M -51.77% 1.32M -51.77% 1.32M 15.8% 2.6M
Restricted cash
-63.24% 50K -63.24% 50K -63.24% 50K -73.12% 50K
Total current assets
-28.54% 45.12M -17.16% 50.99M -17.16% 50.99M -13.38% 56.48M
Non current assets
Net PPE
31.13% 6.11M 18.95% 5.78M 18.94% 5.78M 17.83% 5.95M
-Gross PPE
30.83% 7.22M 20.52% 6.82M 18.94% 5.78M 19.65% 6.93M
-Accumulated depreciation
-29.21% -1.11M -30.11% -1.04M -- -- -32.07% -976K
Goodwill and other intangible assets
0% 4.35M 0% 4.35M 0% 4.35M 0% 4.35M
-Goodwill
0% 1.34M 0% 1.34M 0% 1.34M 0% 1.34M
-Other intangible assets
0% 3.02M 0% 3.02M 0% 3.02M 0% 3.02M
Other non current assets
0.01% 200.32K -0.11% 199.73K 0% 200K -0.02% 199.72K
Total non current assets
15.74% 10.67M 9.78% 10.33M 9.78% 10.33M 9.38% 10.5M
Total assets
-22.9% 55.78M -13.59% 61.33M -13.59% 61.33M -10.46% 66.98M
Liabilities
Current liabilities
Payables
220.63% 1.35M 168.12% 938.27K 168.12% 938.27K 77.45% 662K
-accounts payable
220.63% 1.35M 168.12% 938.27K 168.12% 938.27K 77.45% 662K
Current accrued expenses
-6.64% 1.14M -10.83% 1.92M 1.99% 2.85M -13.03% 1.66M
Current debt and capital lease obligation
46.17% 575.84K 32.49% 559.59K 32.49% 559.59K 20.65% 543.1K
-Current capital lease obligation
46.17% 575.84K 32.49% 559.59K 32.49% 559.59K 20.65% 543.1K
Current deferred liabilities
277.42% 702K 44.95% 932K -- -- 1084.62% 1.23M
Other current liabilities
1.18% -252 -134.04% -112 -- -- -195.1% -97
Current liabilities
69.65% 3.77M 21.89% 4.35M 21.89% 4.35M 44.42% 4.1M
Non current liabilities
Long term debt and capital lease obligation
23.56% 3.99M 24.5% 4.14M 24.5% 4.14M 25.39% 4.29M
-Long term capital lease obligation
23.56% 3.99M 24.5% 4.14M 24.5% 4.14M 25.39% 4.29M
Non current deferred liabilities
0% 341.27K 0% 341.27K 0% 341.27K 0% 341.27K
Total non current liabilities
21.31% 4.33M 22.22% 4.48M 22.22% 4.48M 23.09% 4.63M
Total liabilities
39.84% 8.1M 22.06% 8.83M 22.06% 8.83M 32.26% 8.73M
Shareholders'equity
Share capital
-99.41% 21.69K -99.43% 21.63K -99.43% 21.63K -99.46% 21.63K
-common stock
6.16% 21.69K 8.08% 21.63K 8.08% 21.63K 8.69% 21.63K
-Preferred stock
-- -- -- -- -- 0 -- 0
Retained earnings
-22.36% -137.61M -22.44% -131.63M -22.44% -131.63M -23.49% -124.93M
Paid-in capital
6.11% 185.9M 10.2% 184.25M 10.2% 184.25M 11% 183.17M
Gains losses not affecting retained earnings
-561.25% -629.17K -163.77% -145.5K -163.77% -145.5K -100.44% -1.59K
Total stockholders'equity
-28.36% 47.68M -17.63% 52.49M -17.63% 52.49M -14.59% 58.25M
Total equity
-28.36% 47.68M -17.63% 52.49M -17.63% 52.49M -14.59% 58.25M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%